Study Details

PROTOCOL SUMMARY

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored interventional studies.

Participation Requirements

Age

N/A

Sex

All

Healthy Volunteers

Medical Condition

Solid and Hematological Malignancies

Gender

N/A

Date

December 2021 - December 2040

Study Type

Interventional

Study Phase

Phase 2

Product

Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, KITE-585, KITE-718, KITE-439, KITE-222, KITE-363

Eligibility Information

Inclusion Criteria

The individual must have received an infusion of gene-modified cells in a completed Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or completed the post-treatment follow-up period in the parent study, as applicable
The individual must understand and voluntarily sign an Informed Consent Form (ICF) or an Informed Assent Form prior to any study-related assessments or procedures being conducted
In the investigator's judgment, the individual is willing and able to complete the protocol-required follow-up schedule and comply with the study requirements for participation

Exclusion Criteria

No Exclusion Criteria present

Locations

Locations (53)

Banner MD Anderson Cancer Center

Gilbert, Arizona, United States, 85234

City of Hope

Duarte, California, United States, 91010

UC San Diego Moores Cancer Center

La Jolla, California, United States, 92093

University of California Los Angeles

Los Angeles, California, United States, 90095

Stanford University

Palo Alto, California, United States, 94305

University of California Davis Comprehensive Cancer Center

Sacramento, California, United States, 95817

University of California, San Francisco Medical Center

San Francisco, California, United States, 94143

Colorado Blood Cancer Institute

Denver, Colorado, United States, 80218

Sylvester Comprehensive Cancer Centre

Miami, Florida, United States, 33136

Moffitt Cancer Center

Tampa, Florida, United States, 33612

University of Chicago Medical Center Clinical Laboratories

Chicago, Illinois, United States, 60637

Loyola University Medical Center

Maywood, Illinois, United States, 60153

University of Iowa

Iowa City, Iowa, United States, 52242

The University of Kansas Cancer Center Westwood

Westwood, Kansas, United States, 66205

University of Maryland Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, United States, 21201

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215

Karmanos Cancer Center Institute

Detroit, Michigan, United States, 48201

Washington University

Saint Louis, Missouri, United States, 63110

University of Nebraska

Omaha, Nebraska, United States, 68198

John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601

Montefiore Medical Center

Bronx, New York, United States, 10467

Columbia University Medical Center

New York, New York, United States, 10032

Memorial Sloan-Kettering Cancer Center

New York, New York, United States, 10065

University of Rochester Medical Center

Rochester, New York, United States, 14642

Mayo Clinic

Rochester, New York, United States, 55905

DUHS-Duke Blood Cancer Center

Durham, North Carolina, United States, 27710

Cleveland Clinic

Cleveland, Ohio, United States, 44195

James Cancer Hospital and Solove Research Institute

Columbus, Ohio, United States, 43220

Tennessee Oncology, PLLC

Nashville, Tennessee, United States, 37203

Vanderbilt University

Nashville, Tennessee, United States, 37232

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

Swedish Cancer Institute

Seattle, Washington, United States, 98104

Fred Hutchinson Cancer Center

Seattle, Washington, United States, 98109

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia, 3000

Princess Margaret Cancer Center - University Health Network

Toronto, Canada, M5G 2C4

Vancouver General Hospital

Vancouver, Canada, V5Z 1M9

Hopital Saint-Louis

Paris, France, 75010

CHU Bordeaux, Hopital Haut-Leveque

Pessac, France, 33604

Hôpital Pontchaillou - CHU de Rennes

Rennes, France, 35033

Universitatsklinikum Carl Gustav Carus

Dresden, Germany, 01307

LMU Klinikum der Universitat Munchen,Med. Klinik und Poliklinik III

München, Germany, 81377

Universitatsklinikum Wurzburg, Med. Klinik und Poliklinik II, Zentrum lnnere Medizin

Wuerzburg, Germany, 97080

Tel Aviv Souraski Medical Center

Tel Aviv, Israel, 6423906

Kyushu University Hospital

Fukuoka, Japan, 812-8582

Kyoto University Hospital

Kyoto, Japan, 606-8507

Okayama University Hospital

Okayama, Japan, 700-8558

Hokkaido University Hospital

Sapporo Hokkaido, Japan, 060-8648

National Cancer Center Hospital

Tokyo, Japan, 104-0045

Amsterdam Universitair Medische Centra (UMC)

Amsterdam, Netherlands, 1100

University Medical Centre Groningen

Groningen, Netherlands, 9700 RB

Erasmus University Medical Centre (MC)

Rotterdam, Netherlands, 3011PL

UMC Utrecht

Utrecht, Netherlands, 3508 GA

The Royal Marsden NHS Foundation Hospital

London, United Kingdom, SW10 9NH

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

OVERVIEW